BGB Group’s Post

We are ALWAYS looking for ways to elevate the work we do for our clients. Last week, we dipped into the world of design... Brian Keys, Jerlyn O., and Jacob Molloy had the exciting opportunity to explore what the future of design looks like at Figma Config and Adobe Make It. We observed new features and a suite of AI-powered tools that promise to offer more streamlined experiences, revolutionize our design workflow, and enhance our collaboration. We're excited to continue to explore possibilities and integrate new ways of working into our every day. #designexperts #futurefocused #creativetransformation

#LoveisLove This PRIDE month, we're celebrating LGBTQ+ excellence in medicine! Check out our video highlighting influential LGBTQ+ professionals who have shaped medical history and championed inclusion in healthcare. Learn why Dr. Alan Hart, Dr. Magnus Hirschfeld, Dr. Rachel Levine, Peter Stanley, Dr. Michael Gottlieb, and Dr. Linda Laubenstein inspire us. We celebrate inclusion this month and every month. It's in our DNA! #bgbyourself #bgbproud

Last week, our BGBers Angela Nurse and Gina Lee Barrientos, PharmD, RPh attended the Black in Cancer Conference which drew world renowned speakers, students, clinicians, researchers, and industry leaders. The organization works hard to build support networks increasing the number of black cancer researchers, facilitates mentorship and collaborations for student scientists, and gives cancer survivors and patient advocates a platform to share their experiences and insights. Our team noted they felt the excitement, eagerness, and motivation from all attendees from the minute they walked in. We are very proud to have sponsored an event with such a powerful mission and theme of “Lifting as We Climb” which emphasized the critical role we ALL play in creating sustainable pathways for future black cancer pioneers.

The value of real-world evidence has been on everyone's mind now more than ever! Eleanor (Tyler) Maughan, PhD talks to us about how we can better leverage RWE to drive innovation in early research, clinical trials, regulatory approvals, commercialization and post-market surveillance. Read more here: https://rb.gy/yuboa0

Have you checked out MM+M's 2024 Agency 100 list? We're so thrilled for another year as a top 25 agency in the country!! This year, the much anticipated creative exercise called for the design of a sports jersey... BGB has the brains. And we bring a storm of creative and strategic innovation. Thriving on the electricity of cutting-edge thinking, every day we change the game for our clients... Check out our profile here: https://lnkd.in/ep_c2hhH

Were you at the American Society of Clinical Oncology (ASCO) plenary yesterday afternoon? SO much applause!!! Our VP, Medical Director Denise (Minton) Lee-Thorp doubles as a professional news anchor and tuned us in to the data she found most exciting... Reach out to us to learn more about how we anticipate these key data will translate into clinical practice. #thatsawrap #ASCO #oncexperts

We're among the tens of thousands of dedicated individuals from all over the world who come together to talk about advancements in the field of oncology during these few days... Yesterday morning, our Senior Medical Director, Jeremy Gaerlan joined attendees to watch a series of eagerly awaited Late-Breaking Abstract (LBA) presentations. First were the results from the DESTINY-Breast06 study. Dr. Giuseppe Curigliano, lead author, received both applause and intrigue after presenting the primary results from DESTINY-Breast06—echoing the enthusiasm seen in 2022 with the unveiling of the DESTINY-Breast04 study and the introduction of the HER2-low category. We've seen applause year after year in this space. The DESTINY-Breast06 study revealed that patients with HR+/HER2-low status experienced a significant and clinically meaningful extension in mPFS with trastuzumab deruxtecan (T-DXd) compared to chemotherapy (13.2 months vs. 8.1 months, respectively; HR=0.62; P<0.0001). Additionally, a subgroup analysis indicated a similar improvement in mPFS for patients with HR+/HER2-ultralow status (13.2 months vs. 8.3 months; HR=0.78). These findings mark the first instance of a HER2-targeted ADC demonstrating clinical efficacy in the HER2-ultralow category. Breast cancer encompasses various subtypes, distinguished by HER2 protein expression levels. The novel HER2-ultralow category further refines the existing HER2 status classifications. Previously categorized as HER2-negative, HER2-low and HER2-ultralow cancers are now being recognized to exhibit low HER2 expression. The study’s implications have sparked widespread discussion among media and conference participants regarding the accurate diagnosis of HER2-, HER2-low, and HER2-ultralow statuses. Dr. Ian Krop, discussant for the presentation, highlighted the challenges pathologists may face, particularly the current limitations of HER2 testing assays. Needless to say, it will be interesting to see how guideline committees and the oncology field would adapt to a new HER2-ultralow designation! #breastcancerexpert #oncexpert

American Society of Clinical Oncology (ASCO) 2024 presentations kicked off today, and we dove right in! Our Medical Director, Wanette Vargas Riad, Ph.D. shared buzz around the CML space... When we look at chronic myeloid leukemia (CML), Tyrosine kinase inhibitors (TKIs) are currently the standard of care (SOC) and have significantly advanced the treatment landscape, increasing survival for a large proportion of patients, who can live as long as people without CML. Unmet needs still remain. Patients with good response/survival may need to stay on treatment long-term, which can create financial and/or adverse events (AE) burden, or lead to resistance. This afternoon, Dr. Hughes presented the primary results of ASC4FIRST, a phase 3 trial that is evaluating asciminib vs standard-of-care TKIs in newly diagnosed patients with CML. This is the first study in CML that compares all current SOC frontline TKIs with a novel TKI. Both primary endpoints in the ASC4FIRST trial were met, with clinically meaningful and statistically significant results and suggested an improved safety profile, with fewer grade 3+ AEs or AE-related discontinuations. During the discussion, Dr. Vachhani highlighted that the improved tolerability profile of asciminib was an unexpected and welcomed surprise and would be on his "wishlist" for a new first-line (1L) TKI. While long-term follow up will be needed in order to better determine the impact of asciminib in the current treatment landscape for CML, we can be hopeful about the potential of additional agents in frontline CML that may address some of the current unmet needs! #oncexperts #oncology #ASCO2024 #cml

We're very proud to be sponsoring the first US-based Black in Cancer conference coming up later this month at the Natcher Conference Center in Bethesda, Maryland. The organization works hard to build support networks increasing the number of black cancer researchers, facilitates mentorship and collaborations for student scientists, and gives cancer survivors and patient advocates a platform to share their experiences and insights. The 2024 conference theme of “Lifting as We Climb” emphasizes the critical roles we ALL have in creating sustainable pathways for future black cancer pioneers. We look forward to sharing our experience. Stay tuned for more!! Linda Beach, Ph.D. Angela Nurse Gina Lee Barrientos, PharmD, RPh Maurice Butler, PhD Amanda Eckel